Eli Lilly’s Lyumjev receives FDA approval
Eli Lilly has received FDA approval and expanded labelling for its Lyumjev rapid-acting insulin. Lyumjev is a novel formulation of insulin lispro for speeding up
Eli Lilly has received FDA approval and expanded labelling for its Lyumjev rapid-acting insulin. Lyumjev is a novel formulation of insulin lispro for speeding up
Fractyl Health has activated the 10th clinical site in its REVITA-T2Di trial in the United States and Europe. The trial is a prospective, randomised, double-blind,